Partner Nate Lacktman was quoted in a MobiHealthNews article, “Clinical Decision Support Coalition Letter Criticizes FDA’s Stance on CDS,” as one of the supporters of the FDA’s recent Clinical Decision Support draft guidance. This guidance outlines forms of CDS which won’t be regulated based on the degree of human involvement instead of based on risk.
Lacktman said, “Digital health companies and telemedicine providers should take a moment today and tweet a big thank you to Commissioner Scott Gottlieb (@SGottliebFDA) and the FDA for this long-awaited guidance. Not only has the FDA made great leaps to educate digital health software developers, Commissioner Gottlieb’s direction clearly recognizes the need not to over-regulate our industry and instead maintain the delicate balance between protecting patient safety and promoting health innovation.”
Lacktman said, “Digital health companies and telemedicine providers should take a moment today and tweet a big thank you to Commissioner Scott Gottlieb (@SGottliebFDA) and the FDA for this long-awaited guidance. Not only has the FDA made great leaps to educate digital health software developers, Commissioner Gottlieb’s direction clearly recognizes the need not to over-regulate our industry and instead maintain the delicate balance between protecting patient safety and promoting health innovation.”
People
Related News
June 23, 2025
In the News
Thomas Ferrante Shares Insight on Compliance Considerations for Remote Patient Monitoring
June 20, 2025
In the News
Brian Wheeler and Lyman Thai Comment on Private Equity's Entry into Niche Sports
Foley & Lardner LLP partners Brian Wheeler and Lyman Thai described private equity's growing investments in niche sports in the Pensions & Investments article, "Ares Management buys minority stake in French sailing team."
June 17, 2025
In the News
JillAllison Opell and Jonathan Goeringer Author Article on Legal Risks of Insurance Referral Fees
Foley & Lardner LLP partners JillAllison Opell and Jonathan Goeringer authored the New York Law Journal article, "Is Your Referral Fee Just a Disguised Commission?"